• Like
  • Save
Hepatocellular final r0312_7914
Upcoming SlideShare
Loading in...5
×
 

Hepatocellular final r0312_7914

on

  • 192 views

 

Statistics

Views

Total Views
192
Views on SlideShare
192
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Hepatocellular final r0312_7914 Hepatocellular final r0312_7914 Document Transcript

    • HEPATOCELLULAR CARCINOMA TREATMENT REGIMENS The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The cancer treatment regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient. NOTE: GREY SHADED BOXES CONTAIN UPDATED REGIMENS. General treatment note: Sorafenib is the standard of care for unresectable and metastatic hepatocellular carcinoma in patients with Child-Pugh score A. NCCN category 1 recommendation.1, 2 REGIMEN DOSING Unresectable Hepatocellular Carcinoma; Not Candidates for Transplant Sorafenib (Nexavar)1–3 Sorafenib 400mg orally twice daily for Child-Pugh Class A. Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Treatment interruption and/or dose reduction may be needed to manage suspected adverse drug reactions. Available safety data are limited for Child-Pugh Class B or Class C patients and dosing is uncertain. Chemotherapy and radiotherapy1 Only in the context of a clinical trial. Advanced Metastatic Hepatocellular Carcinoma Sorafenib1 Sorefenib 400mg orally twice daily. References 1. NCCN Clinical Practice Guidelines in Oncology™. Hepatobiliary. v 2.2012.Available at: http://www.nccn.org/professionals/ physician_gls/pdf/hepatobiliary.pdf.Accessed February 27, 2012. 2. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. 3. Nexavar [prescribing information].Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2011. (Revised 3/2012) Copyright © 2012 by Haymarket Media Inc.